Gibson Dunn Advises Avere Therapeutics on Reverse Merger with NextCure, and Concurrent Private Financing
July 20, 2026
July 20, 2026
LOS ANGELES, California, July 20 [Category: BizLaw/Legal] -- Gibson, Dunn and Crutcher, a law firm, issued the following news:
* * *
Gibson Dunn Advises Avere Therapeutics on Reverse Merger with NextCure, and Concurrent Private Financing
*
Gibson Dunn is advising Avere Therapeutics, Inc. on its reverse merger transaction with NextCure, Inc. (NASDAQ: NXTC) and concurrent $320 million private financing of shares of common stock and pre-funded war . . .
* * *
Gibson Dunn Advises Avere Therapeutics on Reverse Merger with NextCure, and Concurrent Private Financing
*
Gibson Dunn is advising Avere Therapeutics, Inc. on its reverse merger transaction with NextCure, Inc. (NASDAQ: NXTC) and concurrent $320 million private financing of shares of common stock and pre-funded war . . .